Fourteen drugmakers agree to discounts, but Americans won’t see savings soon – and major healthspan cost drivers remain largely untouched.
President Donald Trump has been calling his new drug-pricing deals “the greatest victory for patient affordability in the history of American health care, by far.” Fourteen major drugmakers, including Pfizer, Novartis and Eli Lilly, have signed on to agreements promising lower prices for certain medicines under Medicaid, discounted cash purchases directly from drugmakers, and an emphasis on domestic production.
At first glance, it sounds like a win for consumers. The deals could save Medicaid money in the short run and shift how Americans pay for drugs. But health policy experts warn that most Americans will likely not notice the difference in their wallets anytime soon.
Chris Meekins, a Raymond James health care analyst and former health official in the first Trump administration, told Politico that “the vast majority of consumers are not going to see any benefit in their pocketbook [1].”
The catch: longevity drugs are chronic, costly and unevenly covered
For geroscience and healthspan, drug pricing isn’t just a line-item policy fight – it’s one of the biggest levers shaping late-life health outcomes. The therapies driving US spending growth are tightly linked to aging biology: cardiometabolic disease, neurodegeneration and chronic inflammatory conditions. Even modest policy shifts can influence who gets access to long-term disease-modifying drugs – and which classes of interventions companies choose to pursue.
Part of the reason the deals won’t feel immediate is that the agreements are confidential and largely targeted to Medicaid, leaving the roughly two-thirds of Americans with private insurance largely untouched. And because drugmaker participation is voluntary, there is no guarantee the deals will last beyond this administration.
That limitation matters because the highest-impact “healthspan” drugs are often used chronically, at scale – and they increasingly sit at the center of payer battles. GLP-1 and dual incretin drugs for obesity and diabetes, for example, are already reshaping cardiometabolic risk and demand curves, yet remain expensive and unevenly covered. Oncology therapies and emerging neurodegenerative drugs carry similarly high price tags, and any sustained pricing reform will ultimately be judged by what it does to adoption in those categories, not just to a narrow Medicaid subset.
The bigger bet: making the world pay more so Americans pay less
Trump officials argue the benefits will come later. By pushing other wealthy countries to pay more for their medicines, they hope to redirect some of those profits into lower US drug prices.
A key tool is the “most-favored-nation” (MFN) pricing approach, which sets US drug prices based on the lowest prices paid in other wealthy countries, adjusted for purchasing power. The administration has framed MFN as a way to reduce what it describes as foreign “free-riding” on US-funded pharmaceutical innovation [2].
Chris Klomp, the director of Medicare at the Centers for Medicare and Medicaid Services, said that every new drug introduced in the US would be priced at an MFN rate, leading to savings for all citizens [1]. He further described the initiative as a structured realignment of global drug pricing designed to improve US access without destabilizing the pharmaceutical industry.
So while most people won’t see immediate relief, the administration’s bet is that drug prices gradually align globally, making medicines more affordable in the long run.
If MFN pricing becomes durable policy, it would disproportionately affect the same drug classes that dominate aging-related costs: cardiometabolic therapies, biologics for chronic inflammatory disease, oncology drugs and emerging neurodegeneration treatments. These are not one-time expenses; they accumulate over years – which is exactly why they matter for healthspan economics and why they are politically attractive targets.
Back to reality
Not everyone sees the MFN approach as a win. Some industry groups warn that the policy could reduce revenue and slow innovation.
Smaller biotech companies have expressed particular concern, asserting that MFN disproportionately impacts small and mid-sized innovators. They note that these organizations are responsible for the discovery and development of more than half of new pharmaceuticals.
Meanwhile, the Inflation Reduction Act (IRA) of 2022 is beginning to have a measurable effect. Starting next month, CMS will negotiate prices for high-cost, single-source prescription drugs and require drugmakers to give back money when price increases exceed inflation [3].
Experts say the IRA’s impact will be substantial for Medicare members, but the effect on the broader US population is limited.
Trump’s new portal, TrumpRx.gov, launching this month, will allow certain patients – primarily uninsured or underinsured – to buy drugs at discounted prices straight from manufacturers. However, experts note that for those with insurance, cash purchases often do not count toward deductibles, so many people would still benefit more through their insurance.
Some consumer advocates are skeptical about how long these deals will last, arguing that secretive, informal agreements are unlikely to produce meaningful results. Others worry that the deals could reshape US drug pricing structures for years – reorganizing underlying systems so significantly that they could be difficult to reverse.
There is also a long-term question at the heart of the longevity conversation: can the US redesign incentives so that prevention becomes economically rational at population scale? If drug pricing policy lowers barriers to therapies that reduce late-life complications – whether cardiometabolic drugs that prevent cardiovascular events today, or future geroscience-derived interventions that delay multimorbidity – the savings may take years to emerge, but the impact on healthspan could be substantial.
While Trump’s drug-pricing deals and federal negotiations may not deliver immediate savings for most Americans, they could quietly reshape how the US pays for medicine in the years to come… well, if they stick.
[1] https://www.politico.com/news/2026/01/04/trumps-drug-pricing-deals-wont-benefit-most-americans-today-that-could-over-time-00706529
[2] https://www.hhs.gov/press-room/cms-mfn-lower-us-drug-prices.html
[3] https://news.bloomberglaw.com/health-law-and-business/trump-biden-drug-price-control-efforts-set-to-collide-in-2026
